复方首乌降脂通脉颗粒防治大鼠高脂血症和脂肪肝的实验研究-东南大学学报医学版

复方首乌降脂通脉颗粒防治大鼠高脂血症和脂肪肝的实验研究

单位：南京工业大学,江苏省药物研究所,江苏,南京,210009

分类号：R965.1, R575.5, R589.2

出版年·卷·期（页码）：2007·26·第五期（339-343）

摘要：

目的:研究复方首乌降脂通脉颗粒对大鼠高脂血症和脂肪肝的防治作用.方法:大鼠在小剂量四氯化碳致肝损伤的基础上,合并喂养高脂饲料复制大鼠脂肪肝模型.防治给药组分别给予不同浓度的药物,以血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)、丙二醛(MDA)和超氧化物歧化酶(SOD)含量为评价指标,观察药物的防治效果.结果:与大鼠脂肪肝模型组相比,复方首乌降脂通脉颗粒可以显著降低大鼠血清TC、TG、LDL、MDA、ALT和AST含量,升高SOD活性.肝脏组织及病理形态学改变均有明显的改善.结论:复方首乌降脂通脉颗粒能明显降低高脂血症大鼠的血脂水平,减轻脂肪肝形成的程度,对复合因素引起的脂肪肝有较好的防治作用.

Objective To investigate the antihyperlipidemia and antifatty liver of complex Shouwu jiangzhitongmai granule(CSJG) in rats.Methods Male SD rats were fed with high-fat diet for 6 weeks after being treated with low dose of carbon tetrachloride(CCl4) to induce the fatty liver model.The different dosages of the drug were then orally given to the rats.Serum contents of total cholesterol(TC),triglycerides(TG),high-density lipoprotein(HDL),low-density lipoprotein(LDL),alanine transaminase(ALT),aspartate transaminase(AST),malonyldialdehyde(MDA),and superoxide dismutase(SOD) were measured as indexes to evaluate the drug effects.Results The serum levels of TC,TG,LDL,MDA,ALT,and AST were significantly decreased and the activity of SOD was markedly increased by the CSJG.The substantial improvement of liver histology and the pathological morphology were also observed in treated rats.Conclusion CSJG can significantly reduce the levels of serum lipids as well as alleviate the degree of fatty liver formation,indicating that it has great effects on the experimental fatty liver induced by administration of the combination of a low dose CCl4 and high-fat diet.

参考文献：

[1] 陈灏珠. 实用内科学, 2004
[2] 廖华, 杜晓锋. 高脂血症与脂肪肝的相关性研究. 中国误诊学杂志2002(9). doi:10.3969/j.issn.1009-6647.2002.09.064
[3] COMAR K M, STERLING R K. Review article:drug therapy for non-alcoholic fatty liver disease. 2006
[4] 曾民德. 降血脂药物在脂肪肝治疗中的应用. 中华肝脏病杂志2000(2)
[5] 鄢盛恺. 关于临床血脂测定的建议. 中华检验医学杂志2003(3)
[6] CHOJKIER M, LYCHE K D, FILIP M. Increased production of collagen in vivo by hepatocytes and nonparenchym al cells in rats with carbon tetrachloride-induced hepatic fibrosis. 1988(4). doi:10.1002/hep.1840080419
[7] 苏菁, 徐宗佩. 中医高脂血症治疗进展. 时珍国医国药2006(7). doi:10.3969/j.issn.1008-0805.2006.07.116
[8] AHN K S, KIM J H, OH S R. Inhibitory activity of stilbenes from medicinal plants on the expression of cell adhesion moleculeson THP1 cells. 2000(7). doi:10.1055/s-2000-8634
[9] 刘治军, 张丽, 李林. 中药何首乌的药理作用研究进展, 2004(5)
[10] 谢田, 牛孝亮, 刘占滨. 茵陈的药理作用及临床应用进展. 黑龙江中医药2004(4)
[11] 杨英昕, 毕秀丽, 朱培庭. 非酒精性脂肪肝动物模型研究纂要. 中医药学刊2005(4). doi:10.3969/j.issn.1673-7717.2005.04.035
[12] 吴强, 彭西, 崔恒敏. 动物脂肪肝发病机理的研究进展. 家禽科学2006(4). doi:10.3969/j.issn.1673-1085.2006.04.017
[13] 张卓, 李道本. 脂肪肝与脂质过氧化. 中国中西医结合消化杂志2003(4). doi:10.3969/j.issn.1671-038X.2003.04.029
[14] 赵艳玲, 蔡光明, 刘军. 正交试验法优选小鼠四氯化碳肝损伤模型. 解放军药学学报2001(4). doi:10.3969/j.issn.1008-9926.2001.04.016
[15] 仲来福, 张瑾岗, 张富勤. 四氯化碳致大鼠肝损伤的机理. 中国药理学与毒理学杂志1989(3)
[16] 郑幼兰, 朱惠, 黄庆标. 他汀类药物调脂作用研究进展. 海峡药学2002(6). doi:10.3969/j.issn.1006-3765.2002.06.002

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录